Editas Medicine (NASDAQ: EDIT)
Key Data Points
Editas Medicine Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Editas Medicine Company Info
Editas Medicine is a pioneer in gene editing technology. The biotech holds exclusive rights to CRISPR, a mechanism for cutting and pasting changes to DNA at precise locations.
News & Analysis
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
The company has great potential if and when it enters the commercial stage.
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
The company now has a chance to get its lead program out the door a bit sooner.
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
The clinical-stage genome editing company dropped a couple of important announcements for shareholders.
1 Beaten-Down Stock With 55% Upside, According to Wall Street
The biotech has bounced back some in the past year.
2 Under-the-Radar Stocks With Incredible Upside Potential
It's also important to consider their downsides.
Could Editas Medicine Become the Next CRISPR Therapeutics?
The similarities between the pair are striking, but it might not be enough.
Down 88%, Could Editas Medicine Be a Good Investment Now?
The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles.
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
These two are at very different stages of the clinical trials process.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Podcast Episodes
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.